( BRANFORD Conn.--(BUSINESS WIRE)--May 2...)Neurogen Proprietary Insomnia Compound Data Presented at American,Psychiatric Association Annual Meeting,Health

BRANFORD, Conn.--(BUSINESS WIRE)--May 23, 2007 - Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 and Phase 2a clinical studies for NG2-73, the Company's lead compound for the treatment of insomnia, were presented today at the American Psychiatric Association (APA) annual meeting in San Diego. Two Phase 2b clinical studies with NG2-73 in chronic insomnia patients are currently being conducted by the Company. Data presented at the APA meeting include the following abstracts:

--NG2-73, a Novel GABA(A) Partial Agonist, Rapidly Induced Sleep in a Transient Insomnia Study (Phase 2a)

NG2-73 is a partial GABA(A) agonist with preference for receptors containing the (alpha)3 subunit. Preclinical studies suggest that this compound has sedative hypnotic effects, supporting development as a potential treatment for insomnia.

This double-blind, placebo-controlled, randomized, multi-center study was designed to determine the effects of 1,3,10 and 20mg of NG2-73 compared to placebo on sleep onset as measured by Latency to Persistent Sleep (LPS) in healthy adults. The study design incorporated a single-night, polysomnography (PSG) model of transient insomnia using both first night sleep laboratory adaptation and "phase-advance" effects. Subjects were dosed in the sleep laboratory 2.5 hours prior to median habitual bedtime. "Lights off" and PSG recording started 30 minutes later. Safety was monitored by adverse event recording, physical exams, vital signs, electrocardiogram (ECG) and clinical laboratory tests. 369 healthy subjects aged 24-63 with no self-reported sleep disorders were enrolled.

LPS was statistically significantly reduced, compared to placebo, at all doses of NG2-73, and demonstrated a dose-response relationship. The mean times for LPS were 30.8 minutes for the Placebo group, and 17.8, 10.6, 7.8, and 6.6 minutes for the 1, 3, 10, and 20 mg NG2-73 groups, resp
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
2. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
10. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results